VANCOUVER, BC--(Marketwired - August 28, 2017) - Aequus Pharmaceuticals Inc. (
"We are excited to work with Ehave as we advance various development programs, both our traditional pharmaceutical products and medical cannabinoid containing products, through clinical trials," says Doug Janzen, Chairman and CEO of Aequus. "This partnership will allow Aequus to capture patient outcomes of product safety and efficacy in a variety of trial settings in a very efficient and cost-effective way. We believe the Ehave platform is ideally suited for monitoring and assessing product performance in the rapidly evolving medical cannabis space, tracking both patient safety and product efficacy and providing clinicians and drug developers like Aequus and our partners with robust clinical data in a real-world setting, something that is currently lacking and that the medical community has been asking for."
"Our core technology platform allows us to provide customized, next-generation clinical solutions that empower pharmaceutical developers to be successful by streamlining patient management and data collection, reducing errors and data loss, improving patient compliance, and ultimately saving valuable time and costs," said Prateek Dwivedi, CEO of Ehave. "We're pleased to partner with Aequus and to support the clinical evaluation of its pharmaceutical and cannabinoid drug candidates. We believe this partnership will demonstrate how the Ehave platform may mitigate certain data management challenges facing researchers in neurology, and how Ehave can help validate and unlock value for new pharmaceutical and medical cannabis products."
About Aequus Pharmaceuticals
Aequus Pharmaceuticals Inc. (
About Ehave, Inc.
Ehave (
Forward-Looking Statements:
This release may contain forward-looking statements or forward-looking information under applicable Canadian securities legislation that may not be based on historical fact, including, without limitation, statements containing the words "believe", "may", "plan", "will", "estimate", "continue", "anticipate", "intend", "expect", "potential" and similar expressions. Forward-looking statements are necessarily based on estimates and assumptions made by us in light of our experience and perception of historical trends, current conditions and expected future developments, as well as the factors we believe are appropriate. Forward-looking statements in this release include but are not limited to statements relating to: identifying barriers to current use and potential product offerings in specific therapeutic areas, and using results from Ehave's bioinformatics platform to monitor and assess patient outcomes. Such statements reflect our current views with respect to future events and are subject to risks and uncertainties and are necessarily based upon a number of estimates and assumptions that, while considered reasonable by Aequus, are inherently subject to significant business, economic, competitive, political and social uncertainties and contingencies. Many factors could cause our actual results, performance or achievements to be materially different from any future results, performance, or achievements that may be expressed or implied by such forward-looking statements. In making the forward-looking statements included in this release, the Company has made various material assumptions, including, but not limited to: obtaining positive results of clinical trials, obtaining regulatory approvals, general business and economic conditions, the Company's ability to successfully out-license or sell its current products and in-license and develop new products, the assumption that the Company's current good relationships with its manufacturer and other third parties will be maintained, the availability of financing on reasonable terms, the Company's ability to attract and retain skilled staff, market competition, the products and technology offered by the Company's competitors and the Company's ability to protect patents and proprietary rights. In evaluating forward-looking statements, current and prospective shareholders should specifically consider various factors set out under the heading "Risk Factors" in the Company's Annual Information Form dated April 29, 2016, a copy of which is available on Aequus' profile on the SEDAR website at www.sedar.com, and as otherwise disclosed from time to time on Aequus' SEDAR profile. Should one or more of these risks or uncertainties, or a risk that is not currently known to us materialize, or should assumptions underlying those forward-looking statements prove incorrect, actual results may vary materially from those described herein. These forward-looking statements are made as of the date of this release and we do not intend, and do not assume any obligation, to update these forward-looking statements, except as required by applicable securities laws. Investors are cautioned that forward-looking statements are not guarantees of future performance and are inherently uncertain. Accordingly, investors are cautioned not to put undue reliance on forward-looking statements.
Contact Information:
Contact Information:
Aequus Investor Relations
Email: investors@aequuspharma.ca
Phone: 604-336-7906